SOUTH SAN FRANCISCO, Oct. 15 /CNW/ - Synosia Therapeutics today announced
the formation of a Scientific Advisory Board (SAB) to provide input and
guidance on the company's clinical development programs.
Synosia develops and intends to commercialize innovative and clinically
differentiated products for unmet medical needs in psychiatry and neurology
from its portfolio of six clinically enabled compounds. To optimize the
likelihood of success, they invited experts known for their impressive
understanding of neuroscience, medicine and drug development to join the SAB
and provide independent assessments of development strategies. Their first
meeting was in September.
"The distinguished team assembled by Synosia for the Scientific Advisory
Board is an extremely well informed group of experts who can provide critical
appraisal of the work the company plans to undertake in the development of
their impressive portfolio," said J.D. Fitzgerald, FRCP, chairman of the SAB.
Dr. Fitzgerald, who has extensive experience in pharmaceutical research and
development, currently serves as a consultant in pharmaceutical research and
is a co-founder of Synosia.
The other members of the Synosia SAB are:
- Thomas R. Kosten, M.D., Jay H Waggoner Chair and Professor of
Psychiatry and Neuroscience at Baylor College of Medicine and
Research Director of the Veterans Affairs (VA) National Substance Use
Disorders Quality Enhancement Research Initiative (QUERI) based at
the Houston VA.
- David Grahame-Smith, CBE, FRCP, Emeritus Professor of Clinical
Pharmacology, University of Oxford, U.K., author of the Oxford
Textbook of Clinical Pharmacology and Drug Therapy and former member
of the Committee on the Safety of Medicine.
- Alan Schatzberg, M.D., Kenneth T. Norris, Jr. Professor and Chairman,
Department of Psychiatry and Behavioral Sciences, Stanford University
School of Medicine, author of the Manual of Clinical
Psychopharmacology and editor of the Textbook of Psychopharmacology.
"We are honored to have such an esteemed group of advisors to help us
extend the reach of the compounds in our portfolio into new therapeutic
areas," said Synosia Chief Executive Officer and President Ian Massey, Ph.D.
"Having our work informed by the independent points of view of these experts
will ensure we apply the highest quality of scientific and medical rigor to
our development programs."
About Synosia Therapeutics
Synosia Therapeutics develops and intends to commercialize innovative and
clinically differentiated products for unmet medical needs in psychiatry and
neurology. The privately-owned company is developing six clinical-stage
compounds acquired through key partnerships with Novartis, Roche and Syngenta,
including two marketed drugs, that will be tested in new indications extending
their reach into new therapeutic areas with combined sales potential in excess
of US$2.5 billion. Synosia has offices in Basel, Switzerland, and South San
Synosia Therapeutics has raised US$32.5 million funding from Versant
Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures (Menlo
Park, CA) and Novo A/S (Copenhagen, Denmark). For more information, visit
For further information:
For further information: Synosia Therapeutics: In Europe: Julie Walters
at Media Speak, Tel: +44-(0)-1494-753-990, Mobile +44-(0)-775-3626967,
email@example.com; In US: Michele Parisi at Media Speak, Tel: (925)